Dendreon ($ JNJ) Zytiga pills pose a threat to already faltering Provenge.
As MM
The expansion of the revamped approach follow DTC specifies doc Dendreon began in July, Richter noted. The company added a sales agent with Urology experience to focus attention once on Provenge, and to educate them about some of the features of the treatment have been quoted Provenge as barriers to uptake. “Current sales derived from the number of Provenge expert Oncology; However, the most recently registered Center of Urology practice, “Richter wrote (as cited MM by
One of these obstacles is the replacement, an important issue given the price tag of $ 93,000 and drug treatment short span, which forced doctors to front the costs to send their cheque. WP Another is the intensive clinical therapy, which includes the withdrawal of blood cells used to individualize the Provenge. Recently, the number of expert oncologist and analysts noted that the relatively low cost Zytiga, plus ease of use, making them formidable rivals for the treatment of Dendreon (Richter referred to the competition from Zytiga “unlimited”).
Related articles:
Mandatory expects sales to remain flat Provenge